Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02962661). This is a study registration, not published results. Lead sponsor: M.D. Anderson Cancer Center. Recruitment status: SUSPENDED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 72 participants (ESTIMATED). Conditions: Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm. Interventions: OTHER: Best Practice; OTHER: Laboratory Biomarker Analysis; DRUG: Mesenchymal Stem Cell Transplantation; DRUG: Mesenchymal Stem Cell Transplantation. Primary outcome measures: Incidence of adverse events , Up to 6 months; Change in left ventricular ejection fraction (LVEF) , Baseline to 6 months. Brief summary: This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.